From HBB Mutation to Precision Medicine: Molecular Pathogenesis, Genetic Modifiers, and Population Genetics of Sickle Cell Disease
Path of Science · 30.09.2026 · 12 (9) · 7001
DOI: 10.22178/pos.134-9 ↗Kurz gefasst
Fachartikel in der Zeitschrift Path of Science, online erschienen am 30.09.2026. Verfasst von God'sglory Ebubechukwu Ilechukwu. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Sickle cell disease (SCD) illustrates how a single nucleotide substitution produces protein dysfunction, systemic pathology, and heterogeneous clinical outcomes. This review outlines the molecular cascade that begins with the HBB c.20A>T (p.Glu6Val) variant, which leads to haemoglobin S (HbS) polymerisation, red-cell sickling, haemolysis, adhesion, inflammation, and vaso-occlusion. It incorporates evidence on genetic modifiers, population genetics, and precision medicine.We searched PubMed/MEDLINE, Web of Science, Scopus, and Google Scholar, and used genetic databases to find nomenclature and allele data. This structured narrative review brings together peer-reviewed original research, systematic reviews, meta-analyses and authoritative guidelines on SCD genetics, pathogenesis, modifiers, population genetics, or precision medicine.Known HbF loci account for a significant proportion of HbF heritability, with the best supported modifiers being fetal haemoglobin (HbF) loci (BCL11A, HBS1L-MYB, Xmn1-HBG2) and α-thalassaemia. The distribution of HbS haplotypes and their association with HbF vary among African populations, and the single origin and multicentric hypotheses are not resolved. The current disease-modifying treatment is hydroxyurea, and gene-based therapy (lentiviral gene addition and CRISPR-based editing of the BCL11A erythroid enhancer) is now approved in some jurisdictions, but requires myeloablative conditioning and specialist centres and is too expensive for many patients in sub-Saharan Africa.Modifier associations and prediction models are only partially transferable because African genomes are underrepresented. Integrated efforts are needed across molecular mechanisms, African genomic diversity, and health-system delivery to advance precision medicine in SCD.
Zitieren
APA
Ilechukwu, G. E. (2026). From HBB Mutation to Precision Medicine: Molecular Pathogenesis, Genetic Modifiers, and Population Genetics of Sickle Cell Disease. Path of Science, 12(9), 7001. https://doi.org/10.22178/pos.134-9
Vancouver
Ilechukwu GE. From HBB Mutation to Precision Medicine: Molecular Pathogenesis, Genetic Modifiers, and Population Genetics of Sickle Cell Disease. Path of Science. 2026;12(9):7001. doi:10.22178/pos.134-9
BibTeX
@article{Ilechukwu2026,
author = {Ilechukwu, God'sglory Ebubechukwu},
title = {From HBB Mutation to Precision Medicine: Molecular Pathogenesis, Genetic Modifiers, and Population Genetics of Sickle Cell Disease},
journal = {Path of Science},
year = {2026},
volume = {12},
number = {9},
pages = {7001},
doi = {10.22178/pos.134-9}
}
EUVIMED